Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3
Authors:
- 21 October 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (40) , 3946-3948
Abstract
Open in new tab Download slide Open in new tab Download slideKeywords
This publication has 14 references indexed in Scilit:
- Putative medicines that mimic mutationsNature, 2017
- Cardiovascular and Metabolic Effects of ANGPTL3 Antisense OligonucleotidesNew England Journal of Medicine, 2017
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelEuropean Heart Journal, 2017
- ANGPTL3 Deficiency and Protection Against Coronary Artery DiseaseJACC, 2017
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biologyJournal of Lipid Research, 2016
- Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular DiseaseNew England Journal of Medicine, 2014
- Loss-of-Function Mutations inAPOC3,Triglycerides, and Coronary DiseaseNew England Journal of Medicine, 2014
- Exome Sequencing,ANGPTL3Mutations, and Familial Combined HypolipidemiaNew England Journal of Medicine, 2010
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006